Download PDF
Dtsch Med Wochenschr 2017; 142(22): 1652-1659
DOI: 10.1055/s-0043-108467
Dossier
© Georg Thieme Verlag KG Stuttgart · New York

Präzisionstherapie beim kolorektalen Karzinom

Personalized Treatment for Colorectal Carcinomas
Sebastian Stintzing
Further Information

Publication History

Publication Date:
27 October 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Colorectal carcinoma (CRC) is a major cause for cancer related death in Western countries. Particularly in the metastatic stage (mCRC) 5-year survival rate remains low at around 15 %. Treatment decisions are influenced by tumor stage, location of the primary, and extend of metastases. The multidisciplinary tumor board with an experienced hepato-biliary surgeon, an interventional radiologist, the medical oncologist, the molecular pathologist and the radiation oncologist will gain further importance in the quest for the optimal treatment for each patient. In the adjuvant setting, next to the established clinical risk factors, individualization especially for UICC-stage II patients can be done according to the CDX2-expression, the MSI-status, and perhaps the PIK3-status. In the metastatic stage, RAS and BRAF mutational analyses are pivotal to choose the best treatment for our patients. Primary tumor location in RAS-wild-type patients is further helping the clinician to tailor first-line treatment. Ongoing phase-III-trials will further help the clinician to come to a personalized decision.

Das kolorektale Karzinom (KRK) ist in Deutschland nach wie vor die zweithäufigste krebsbedingte Todesursache. Die Therapie besteht meist aus einer Kombination von Chirurgie, Strahlenmedizin und medikamentöser Therapie. Die Rolle der molekularen Pathologie wie auch die des interventionellen Radiologen gewinnt zunehmend an Bedeutung. Auch die Ergebnisse der Gensequenzierungs- und Genexpressionsanalysen sind für die Therapiefindung wichtig.

Schlüsselwörter

Dickdarmkrebs - personalisierte Behandlung - RAS - BRAF - MSI-h

Key words

colorectal cancer - personalized treatment - RAS - BRAF - MSI-h
 

  • Literatur

  • 1 RKI und Zentrum für Krebsregisterdaten. 2016 http://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebsgeschehen/Krebsgeschehen_node.html Stand 09.07.2017
    PubMedGoogle Scholar
  • 2 Andre T, Boni C, Mounedji-Boudiaf L. et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351
    CrossrefPubMedGoogle Scholar
  • 3 Shi Q, Sobrero A, Shields AF. et al. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC). J Clin Oncol 2017 35. Supplement; abstr LBA1
    PubMedGoogle Scholar
  • 4 Sargent DJ, Marsoni S, Monges G. et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28: 3219-3226
    CrossrefPubMedGoogle Scholar
  • 5 Le DT, Uram JN, Wang H. et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015; 372: 2509-2520
    CrossrefPubMedGoogle Scholar
  • 6 Dalerba P, Sahoo D, Paik S. et al. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med 2016; 374: 211-222
    CrossrefPubMedGoogle Scholar
  • 7 Liao X, Lochhead P, Nishihara R. et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012; 367: 1596-1606
    CrossrefPubMedGoogle Scholar
  • 8 Paleari L, Puntoni M, Clavarezza M. et al. PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. Clin Oncol (R Coll Radiol) 2016; 28: 317-326
    CrossrefPubMedGoogle Scholar
  • 9 You YN, Rustin RB, Sullivan JD. Oncotype DX((R)) colon cancer assay for prediction of recurrence risk in patients with stage II and III colon cancer. Surg Oncol 2015; 24: 61-66
    CrossrefPubMedGoogle Scholar
  • 10 Koelzer VH, Zlobec I, Lugli A. Tumor budding in colorectal cancer-ready for diagnostic practice?. Hum Pathol 2016; 47: 4-19
    CrossrefPubMedGoogle Scholar
  • 11 Tournigand C, Andre T, Achille E. et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer. J Clin Oncol 2004; 22: 229-237
    CrossrefPubMedGoogle Scholar
  • 12 Van Cutsem E, Cervantes A, Adam R. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27: 1386-1422
    CrossrefPubMedGoogle Scholar
  • 13 Network NCC. NCCN Guidelines Colon Cancer Version 1.2017. 2016. https://www.nccn.org
    PubMedGoogle Scholar
  • 14 Cremolini C, Loupakis F, Antoniotti C. et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer. Lancet Oncol 2015; 16 (13) 1306-1315
    CrossrefPubMedGoogle Scholar
  • 15 Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337
    CrossrefPubMedGoogle Scholar
  • 16 Lievre A, Bachet JB, Le CorreD. et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995
    CrossrefPubMedGoogle Scholar
  • 17 Van Cutsem E, Kohne CH, Hitre E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417
    CrossrefPubMedGoogle Scholar
  • 18 Douillard JY, Oliner KS, Siena S. et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-1034
    CrossrefPubMedGoogle Scholar
  • 19 Rivera F, Karthaus M, Hecht JR. et al. Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. Int J Colorectal Dis 2017; 32: 1179-1190
    CrossrefPubMedGoogle Scholar
  • 20 Stintzing S, Modest DP, Rossius L. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3). Lancet Oncol 2016; 17: 1426-1434
    CrossrefPubMedGoogle Scholar
  • 21 Venook AP, Niedzwiecki D, Lenz HJ. et al. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer. JAMA 2017; 317: 2392-2401
    CrossrefPubMedGoogle Scholar
  • 22 Heinemann V, Rivera F, O'Neil BH. et al. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer. Eur J Cancer 2016; 67: 11-20
    CrossrefPubMedGoogle Scholar
  • 23 Bendell JC, Kim TW, Goh HS. et al. Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). J Clin Oncol 2016; 34 (Suppl. 15) 3502
    CrossrefPubMedGoogle Scholar
  • 24 Loupakis F, Yang D, Yau L. et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst 2015; 107: 107(3)
    PubMedGoogle Scholar
  • 25 Tejpar S, Stintzing S, Ciardiello F. et al. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer. JAMA Oncol 2017; 3 (02) 194-201
    CrossrefPubMedGoogle Scholar
  • 26 Leitgruppe der AG Kolon- Rektum- und Dünndarmtumore der AIO in der DKG. Statement der AIO-KRK-Leitgruppe zur Wahl der Erstlinientherapie bei Patienten mit metastasiertem Kolorektalkarzinom ohne Nachweis einer RAS Mutation unter Berücksichtigung der primären Tumorlokalisation: Update 31. Oktober 2016.
    PubMedGoogle Scholar
  • 27 Jones JC, Renfro LA, Al-Shamsi HO. et al. Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. J Clin Oncol 2017; 35: 2624-2630
    CrossrefPubMedGoogle Scholar
  • 28 Seppala TT, Bohm JP, Friman M. et al. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. Br J Cancer 2015; 112: 1966-1975
    CrossrefPubMedGoogle Scholar
  • 29 Barras D, Missiaglia E, Wirapati P. et al. BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression. Clin Cancer Res 2017; 23: 104-115
    CrossrefPubMedGoogle Scholar
  • 30 Rowland A, Dias MM, Wiese MD. et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 2015; 112: 1888-1894
    CrossrefPubMedGoogle Scholar
  • 31 Pietrantonio F, Petrelli F, Coinu A. et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 2015; 51: 587-594
    CrossrefPubMedGoogle Scholar
  • 32 Kopetz S, Desai J, Chan E. et al. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J Clin Oncol 2015; 33 (34) 4032-4038
    CrossrefPubMedGoogle Scholar
  • 33 Van Geel R, Elez E, Bendell JC. et al. Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer. J Clin Oncol 2014; 32: 5s
    PubMedGoogle Scholar
  • 34 Atreya C, Van Cutsem E, Bendell JC. et al. Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). J Clin Oncol 2016; 33: 2
    PubMedGoogle Scholar
  • 35 Bendell JC, CE A, Andre T. et al. Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC). J Clin Oncol 2014; 32: 5s
    PubMedGoogle Scholar
  • 36 Kopetz S, McDonough SL, Morris VK. et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). J Clin Oncol 2017; 35: 520
    PubMedGoogle Scholar
  • 37 Sehdev A, Cramer HM, Ibrahim AA. et al. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature. Discov Med 2016; 21: 341-347
    PubMedGoogle Scholar
  • 38 Le DT, Durham JN, Smith KN. et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017; 357: 409-413
    CrossrefPubMedGoogle Scholar
  • 39 Overman MJ, Lonardi S, Leone F. et al. Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142. Lancet Oncol 2017 pii: S1470-2045(17)30422-9
    PubMedGoogle Scholar
  • 40 Sartore-Bianchi A, Trusolino L, Martino C. et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES). Lancet Oncol 2016; 17: 738-746
    CrossrefPubMedGoogle Scholar